Intensive Lipitor therapy reduced heart attack and stroke by one-third in patients with chronic kidney disease.
D000924:Anticholesteremic Agents / Q000627:therapeutic use; D000069059:Atorvastatin; D004305:Dose-Response Relationship, Drug; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000503:physiopathology; D009203:Myocardial Infarction / Q000517:prevention & control*; D011758:Pyrroles / Q000627:therapeutic use*; D040242:Risk Reduction Behavior; D020521:Stroke / Q000517:prevention & control*
D000924:Anticholesteremic Agents; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011758:Pyrroles; D000069059:Atorvastatin